Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
PreMarket Prep Stock Of The Day: Editas Medicine
01:14pm, Wednesday, 29'th Sep 2021
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind th
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate
12:25pm, Wednesday, 29'th Sep 2021
Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber congenital amaurosis 10 (LCA10), a CEP290-
Why Shares of Editas Medicine Are Lower This Morning
11:30am, Wednesday, 29'th Sep 2021
Incomplete data is disappointing investors after a long wait.
Implied Volatility Surging for Editas (EDIT) Stock Options
11:15am, Wednesday, 29'th Sep 2021
Investors need to pay close attention to Editas (EDIT) stock based on the movements in the options market lately.
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
09:00am, Wednesday, 29'th Sep 2021
No serious adverse events or dose-limiting toxicities observed to date
Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 Years
05:52am, Thursday, 23'rd Sep 2021
It could perhaps deliver a much bigger gain than 100%.
7 Gene Editing Stocks Promising to Change our DNA
12:45pm, Wednesday, 15'th Sep 2021
Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared
Editas Medicine (EDIT) CEO, Jim Mullen Presents at Morgan Stanley 19th Annual Healthcare Conference - Company Call Transcript
12:40pm, Tuesday, 14'th Sep 2021
Editas Medicine (EDIT) CEO, Jim Mullen Presents at Morgan Stanley 19th Annual Healthcare Conference - Company Call Transcript
Final Trades: Stryker, Editas Medicine, Oracle & more
02:17pm, Monday, 13'th Sep 2021
The "Halftime Report" traders give their top picks to watch for the second half.
Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
05:30pm, Friday, 03'rd Sep 2021
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic R
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
07:30am, Friday, 03'rd Sep 2021
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic R
Editas: Gene Therapy Specialist Leading The Way In Eye Disease
05:09pm, Friday, 27'th Aug 2021
Editas is one of a triumvirate of gene-therapy companies pioneering CRISPR/Cas9 gene-editing technology - the others being CRISPR Therapeutics and Intellia.
Editas Medicine Unveils Preclinical Data From New Gene Editing Technology
06:11am, Monday, 23'rd Aug 2021
Editas Medicine Inc (NASDAQ: EDIT) announced data on a new gene-editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in). Data were presented at the Cold Spring Harbor Laborato
SLEEK enables high efficiency, multi-transgene knock-in of induced Pluripotent Stem Cells (iPSCs), T cells, and Natural Killer (NK) cells
